Home Colorectal Cancer Merck’s Keytruda Gets U.S. FDA Approval for Colorectal Cancer

Merck’s Keytruda Gets U.S. FDA Approval for Colorectal Cancer

20
0


Health Law & Business News

June 29, 2020, 7:38 PM

Merck’s Keytruda for intravenous injection was approved for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, the U.S. Food and Drug Administration said in an emailed statement.

  • It’s the first immunotherapy approved for this patient population as a first-line treatment and which is administered to patients without also giving chemotherapy

To contact the reporter on this story:
Greg Chang in San Francisco at [email protected]

To contact the editor responsible for this story:
Chakradhar Adusumilli at [email protected]

© 2020 Bloomberg L.P. All rights reserved. Used with permission.

To read the full article
log in.

To learn more about a subscription
click here.

https://news.bloomberglaw.com/health-law-and-business/mercks-keytruda-gets-u-s-fda-approval-for-colorectal-cancer

Advertisements

This site uses Akismet to reduce spam. Learn how your comment data is processed.